Article Text

Download PDFPDF
Clinical and Pathological Characteristics of Incidental Diagnostic Early Occult Malignancy After Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers
  1. Ofer Lavie, MD*,
  2. Michael G. Moskoviz, MD*,
  3. Ron Auslender, MD*,
  4. Ofer Gemer, MD*,
  5. Arie Bitterman, MD,
  6. Grace Younes, MD* and
  7. Yakir Segev, MD*
  1. *Division of Gynecology Oncology, Department of Obstetrics and Gynecology, and
  2. Department of Surgery, Carmel Medical Center, Technion University, Rappaport Faculty of Medicine, Haifa, Israel.
  1. Address correspondence and reprint requests to Yakir Segev, MD, Division of Gynecologic Oncology, Carmel Medical Center, Michal St. No. 7, 36342 Haifa, Israel. E-mail:


Objective Carriers of familial BRCA mutations are at high risk of early development of ovarian tubal or peritoneal cancers. The definite preventative treatment for these cases is early, risk-reducing, bilateral salpingo-oophorectomy (BSO). The aims of the study were to describe the incidence and source of early occult malignancy after risk-reducing salpingo-oophorectomy in carriers of Ashkenazi Jewish BRCA mutations and to characterize the clinical and pathological features of this unique population.

Methods Data were collected retrospectively regarding women who underwent BSO in our gynecologic oncology unit from January 2002 through July 2012, after a positive test for a BRCA1 or BRCA2 mutation.

Results The following 92 cases of BRCA mutations were included: 53 BRCA1, 37 BRCA2, and 2 with both mutations. After risk-reducing salpingo-oophorectomy, 5 (5.4%) of the patients were found to have early occult adnexal malignancy upon pathology study. All 5 had the BRCA1 185 del-AG mutation. Three of the 5 malignancies originated from the ovaries and 2 in the fallopian tubes with no involvement of the ovaries.

Conclusions A 5.4% incidence of early occult malignancy in adnexal pathology of BSO was found in carriers of Ashkenazi Jewish BRCA mutations. Two cases with malignant origins within the fallopian tube, while sparing the ovaries in their entirety, support the fallopian tubes as the originating organ for some ovarian or peritoneal malignancies in BRCA mutation carriers.

  • Risk-reducing bilateral salpingo-oophorectomy
  • BRCA carriers
  • Ovarian carcinoma
  • Tubal carcinoma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.